Opdivo (nivolumab) - Ono Pharmaceutical, BMS
Integrating Surgery and Immunotherapy in the Treatment of Childhood Orbital Melanoma: A Case Report and the Literature Review. (PubMed, Ophthalmic Plast Reconstr Surg) - Oct 23, 2026 - "While Nivolumab treated his initial symptoms of care quite effectively, subsequent treatment breaks led to complications, which necessitated a change to a mixed chemotherapy approach. Once Nivolumab was reinstituted, the patient improved significantly, which reinforces the idea that proactive management through surveillance and immunotherapy in combination can control ocular melanoma effectively." 
IO biomarker • Journal • Cervical Cancer • Eye Cancer • Melanoma • Ocular Melanoma • Oncology • Solid Tumor
http://www.ncbi.nlm.nih.gov/pubmed/42906084
 
Bahareh Kermani; Hossein Ghahvehchian; Mansooreh Jamshidian-Tehrani; Seyed Mohammed Kazem Nourbakhsh
 
Oct 23, 2026
 
Prev Next